Precision Oncology: Translating Discovery to the Clinic
Scientific Organizers: Klaus Hoeflich, Scott Lowe and Alice Shaw
Date: May 16 - 20, 2021
Location: Van Andel Institute, Grand Rapids, MI, USA
The discovery of genomic and epigenetic alterations in individual cancers has led to a wellspring of innovation and therapeutic successes in precision medicine. Accordingly, there has been a migration away from “one size fits all” approaches and precision medicine has become increasing multidisciplinary and collaborative. Yet, progress in precision medicine has often been hindered by insufficient overlap between basic researchers, drug hunters and physician scientists having expertise in cancer biology, genomics and other relevant fields. A goal of this conference is to bring together diverse experts from academic, pharma/biotech and government to discuss novel issues, current challenges and future directions in precision medicine for oncology. The symposium will convene two groups of researchers with distinct areas of expertise, namely cancer biologists/clinicians and genomics scientists, to advance information sharing and idea generation, and will address a key knowledge gap that currently exists within this field that is potentially limiting to the advancement of new precision therapies. Discussion topics will include: 1) novel genomic insights, therapeutically-promising mechanisms and cancer drug targets; 2) recent translational breakthroughs; and 3) the incorporation of new diagnostic tools as companions to these new treatments. There will be an emphasis on innovative, first-in-class approaches to novel therapeutics as well as leading-edge advancements in “reverse translation” technologies, such as liquid biopsies and single cell genomics. Ultimately, the goal of the conference is forging new scientific interactions and collaborations to advance the next generation of precision medicines.
Registration for this meeting is not open yet, it will open later in January 2020